Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Haiyitan (gumarontinib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

HaiHe Biopharma, Otsuka

Drug class:

c-MET inhibitor

Related drugs:

‹

›

MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	gumarontinib Sensitive: A1 - Approval gumarontinib Sensitive : A1	gumarontinib Sensitive: A1 - Approval gumarontinib Sensitive : A1
MET amplification	Non Small Cell Lung Cancer	MET amplification	Non Small Cell Lung Cancer	gumarontinib Sensitive: C2 – Inclusion Criteria gumarontinib Sensitive : C2	gumarontinib Sensitive: C2 – Inclusion Criteria gumarontinib Sensitive : C2
MET overexpression	Non Small Cell Lung Cancer	MET overexpression	Non Small Cell Lung Cancer	gumarontinib Sensitive: C2 – Inclusion Criteria gumarontinib Sensitive : C2	gumarontinib Sensitive: C2 – Inclusion Criteria gumarontinib Sensitive : C2
EGFR mutation + MET amplification	Non Small Cell Lung Cancer	EGFR mutation + MET amplification	Non Small Cell Lung Cancer	osimertinib + gumarontinib Sensitive: C3 – Early Trials osimertinib + gumarontinib Sensitive : C3	osimertinib + gumarontinib Sensitive: C3 – Early Trials osimertinib + gumarontinib Sensitive : C3
MET overexpression + SYK overexpression	Non Small Cell Lung Cancer	MET overexpression + SYK overexpression	Non Small Cell Lung Cancer	gumarontinib Sensitive: D – Preclinical gumarontinib Sensitive : D	gumarontinib Sensitive: D – Preclinical gumarontinib Sensitive : D